---
title: "Q-Linea wins Premier contract position for ASTar rapid susceptibility testing system in US"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296207937.md"
description: "Q-Linea secured a contract with Premier, granting over 4,000 member hospitals access to pre-negotiated pricing for its ASTar rapid susceptibility testing system. Effective September 1, 2026, the agreement covers the ASTar instrument and BC G- kit. This deal aims to streamline U.S. procurement processes, shorten sales cycles, and accelerate adoption among Premier's network of institutions."
datetime: "2026-08-18T09:47:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296207937.md)
  - [en](https://longbridge.com/en/news/296207937.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296207937.md)
generator: "portal-rs"
---

# Q-Linea wins Premier contract position for ASTar rapid susceptibility testing system in US

-   Q-linea won a contract position with Premier, giving more than 4,000 member hospitals access to pre-negotiated ASTar pricing. \* Agreement takes effect Sept. 1, 2026, covering the ASTar instrument and the ASTar BC G- kit. \* Deal is expected to shorten U.S. sales cycles by simplifying procurement, supporting faster adoption across Premier member institutions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q-Linea AB published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PINC.US](https://longbridge.com/en/quote/PINC.US.md)

## Related News & Research

- [AI isn’t close to curing cancer. This startup says it knows what it will take.](https://longbridge.com/en/news/296352961.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)
- [Ascentage Pharma posts interim results presentation on 1H 2026 business update](https://longbridge.com/en/news/296418315.md)
- [BioMarin spends up to $490m for Alesta’s bone disease candidate](https://longbridge.com/en/news/296381315.md)
- [RenovoRx gets USPTO notice of allowance for new RenovoCath cancer drug-delivery patent](https://longbridge.com/en/news/296491316.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**